A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med. 2015;373:2103 16. S8.1.2-9. Czernichow S, Zanchetti A, Turnbull F, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4 16. S8.1.2-10. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903 13. S8.1.2-11. van Dieren S, Kengne AP, Chalmers J, et al. Effects of blood pres- sure lowering on cardiovascular outcomes in different cardiovascu- lar risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract. 2012;98:83 90. S8.1.2-12. Montgomery AA, Fahey T, Ben-Shlomo Y, et al. The influence of absolute cardiovascular risk, patient utilities, and costs on the deci- sion to treat hypertension: a Markov decision analysis. J Hypertens. 2003;21:1753 9. S8.1.2-13. Kassai B, Boissel J-P, Cucherat M, et al. Treatment of high blood pressure and gain in event-free life expectancy. Vasc Health Risk Manag. 2005;1:163 9. S8.1.2-13a. ACC/AHA Pooled Cohort Equations. Available at: (http://tools.acc. org/ASCVD-Risk-Estimator/. Accessed November 3, 2017. S8.1.2-14. Rubinstein A, Colantonio L, Bardach A, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk fac- tors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health. 2010;10:627. S8.1.2-15. Baker S, Priest P, Jackson R. Using thresholds based on risk of car- diovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ. 2000;320:680 5. S8.1.2-16. Gaziano TA, Steyn K, Cohen DJ, et al. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation. 2005;112:3569 76. S8.1.2-17. 